These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14612098)

  • 1. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
    Poorrezagholi F; Einollahi B; Firoozan A; Nafar M; Yadegari H; Moghaddam SM; Simforoosh N; Basiri A; Farhangi S
    Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098
    [No Abstract]   [Full Text] [Related]  

  • 2. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H; Bäckman L; Tufveson G; Tydén G
    Transplant Proc; 1999; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract]   [Full Text] [Related]  

  • 3. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F
    Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract]   [Full Text] [Related]  

  • 4. Daclizumab in live donor renal transplantation.
    Iverson AJ; Vick SC; Sarnacki CT; Wright FH
    Transplant Proc; 2000 Jun; 32(4):790-2. PubMed ID: 10856587
    [No Abstract]   [Full Text] [Related]  

  • 5. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
    Lácha J; Símová M; Nosková L; Teplan V; Vítko S
    Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
    [No Abstract]   [Full Text] [Related]  

  • 6. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D
    N Engl J Med; 1998 Jun; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience.
    Baczkowska T; Kukula K; Nowacka-Cieciura E; Cieciura T; Lewandowska D; Ciecierski R; Grochowiecki T; Rowinski W; Szmidt J; Durlik M; Lao M
    Transplant Proc; 2002 Mar; 34(2):551-2. PubMed ID: 12009620
    [No Abstract]   [Full Text] [Related]  

  • 8. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B; Thervet E
    Transplant Proc; 1998 Jun; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract]   [Full Text] [Related]  

  • 9. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F; Nashan B; Light S
    Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
    Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract]   [Full Text] [Related]  

  • 11. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL; Ramos E; Lin A; Vincenti F;
    Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
    Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 15. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
    Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F; Humeres R; Zamboni M; Sanhueza E; Zapata R; Hepp J; Rius M
    Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.
    Hengster P; Pescovitz MD; Hyatt D; Margreiter R
    Transplantation; 1999 Jul; 68(2):310-3. PubMed ID: 10440409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
    Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.